A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor (TRK) family. J Clin Oncol 2017; 10510. Roberts KG, Bridges O, Janke LJ et al. Genetic modeling and therapeutic targeting of ETV6-NTRK3 with Loxo-101 in acute lymphoblastic leukemia. Blood...
A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor (TRK) family. J Clin Oncol 2017; 10510. 34 Roberts KG, Bridges O, Janke LJ, et al. Genetic modeling and therapeutic targeting of ETV6-NTRK3 with Loxo-101 in acute lymphoblastic leukemia....